Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,153 JPY | +1.57% | +0.75% | +2.44% |
09:41am | Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion | RE |
Apr. 26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
Sales 2024 * | 4,099B 26.11B | Sales 2025 * | 4,028B 25.66B | Capitalization | 6,415B 40.87B |
---|---|---|---|---|---|
Net income 2024 * | 134B 854M | Net income 2025 * | 234B 1.49B | EV / Sales 2024 * | 2.48 x |
Net Debt 2024 * | 3,771B 24.02B | Net Debt 2025 * | 3,438B 21.9B | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
46.4
x | P/E ratio 2025 * |
27.6
x | Employees | 49,095 |
Yield 2024 * |
4.6% | Yield 2025 * |
4.64% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | +1.57% | ||
1 week | +0.75% | ||
Current month | -0.74% | ||
1 month | -0.14% | ||
3 months | -3.73% | ||
6 months | +4.14% | ||
Current year | +2.44% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
24.44% | 15 M€ | +11.22% | ||
5.00% | 284 M€ | +25.72% | ||
3.80% | 1,552 M€ | +20.59% | ||
3.43% | 251 M€ | +13.17% | ||
3.26% | 57 M€ | +22.41% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 4,153 | +1.57% | 4 546 600 |
24-04-26 | 4,089 | -0.02% | 3,185,300 |
24-04-25 | 4,090 | -1.09% | 2,910,500 |
24-04-24 | 4,135 | +0.32% | 3,228,000 |
24-04-23 | 4,122 | -0.15% | 2,747,100 |
Delayed Quote Japan Exchange, April 30, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.44% | 40.94B | |
+26.47% | 664B | |
+29.92% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+14.30% | 234B | |
+4.96% | 199B | |
-10.10% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- 4502 Stock